08:00 , Jan 11, 2016 |  BioCentury  |  Strategy

Growing up Galapagos

With a new partner for filgotinib, Galapagos N.V. is poised to enter Phase III testing for the first time, after a five-year period of Phase II disappointments and scuttled deals. The new deal with Gilead...
07:00 , Mar 23, 2015 |  BioCentury  |  Product Development

Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play. The Janus kinase-1 (JAK-1) inhibitor will...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Free fatty acid receptor 2 (FFAR2; GPR43); FFAR3 (GPR41)

Endocrine/metabolic disease INDICATION: Diabetes Cell culture and mouse studies suggest FFAR2 and FFAR3 antagonists could help treat type 2 diabetes. In mouse and human β cell lines, agonizing FFAR2 and FFAR3 with acetate decreased insulin secretion compared...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

GLPG0974: Phase IIa data

Top-line data from a double-blind, placebo-controlled, European Phase IIa trial in 45 patients with mild to moderate UC showed that the reduction in neutrophil influx achieved with twice-daily 200 mg oral GLPG0974 for 4 weeks...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

GLPG0974: Completed Phase IIa enrollment

Galapagos completed enrollment of about 45 patients with mild to moderate UC in a double-blind, placebo-controlled, European Phase IIa trial evaluating 200 mg oral GLPG0974 twice daily for 4 weeks. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen,...
07:00 , Aug 8, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis Free fatty acid receptor 2 (FFAR2; GPR43) Mouse studies suggest short-chain fatty acid supplementation could...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

GLPG0974: Phase IIa started

Galapagos began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 200 mg oral GLPG0974 twice daily for 4 weeks in 45 patients with mild to moderate UC. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium   Product:...
00:01 , Apr 25, 2013 |  BC Extra  |  Top Story

Galapagos raises EUR 53.9M

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said late Wednesday that it raised EUR 53.9 million ($70.5 million) through the sale of 2.7 million shares at EUR 20 in a private placement to institutional investors. Galapagos had proposed...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

GLPG0974: Phase I data

A double-blind, placebo-controlled, Belgian Phase I trial in 32 healthy volunteers showed that once- and twice-daily ascending-doses of oral GLPG0974 for 2 weeks were well tolerated and dose-dependently inhibited neutrophil activation for up to 24...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

GLPG0974: Phase I started

Galapagos began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate multiple ascending-doses of oral GLPG0974 for 2 weeks in 32 healthy volunteers. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium   Product: GLPG0974   Business: Inflammation   Molecular...